Previous 10 | Next 10 |
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 PR Newswire SAN JOSE, Calif. , Jan. 10, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology co...
Anixa Biosciences Inc. (ANIX) is expected to report $-0.09 for Q4 2023 Eaco Corp. (EACO) is expected to report for Q2 2024 Rite Aid Corporation. (RADCQ) is expected to report $-1.45 for Q3 2024 KB Home (KBH) is expected to report $1.67 for Q4 2023 Dogness (International) Corporati...
Anixa Biosciences Inc. (ANIX) is expected to report $-0.09 for Q4 2023
Anixa Biosciences to Present at Biotech Showcase 2024 PR Newswire SAN JOSE, Calif. , Dec. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and...
2023-12-11 12:26:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example. Leading up to U.S. FDA rulings, the st...
2023-12-08 18:24:17 ET Summary Anixa Biosciences is a biotech specializing in immunotherapy treatments for breast and ovarian cancers. They are developing a vaccine for α-lactalbumin in triple-negative breast cancer and AMHR2 in ovarian cancer. ANIX is also involved in ...
2023-12-07 06:50:16 ET More on Anixa Biosciences Seeking Alpha’s Quant Rating on Anixa Biosciences Historical earnings data for Anixa Biosciences Financial information for Anixa Bioscience 8 For further details see: Anixa Bio falls after Phase 1 da...
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine PR Newswire – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T...
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine PR Newswire – Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – C...
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology PR Newswire SAN JOSE, Calif. , Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment a...
News, Short Squeeze, Breakout and More Instantly...
Anixa Biosciences Inc. Company Name:
ANIX Stock Symbol:
NASDAQ Market:
Anixa Biosciences (NASDAQ: ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of ...
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines PR Newswire – Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – SAN JOSE, Calif. , May 8, 2024 ...
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja PR Newswire Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif. , May 6, 2024 /PRNewswire/ -- Anixa Bio...